OncoCyte Stock
Focused on cancers with large patient populations and significant unmet need.
Sign up today and learn more about OncoCyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About OncoCyte Stock
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care costs Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
Management
President & CEO
William Annett
CFO
RUSSELL SKIBSTED
Press
Yankee Analysts - Jun, 27 2018
Oncocyte Corp (OCX) Placed Under the LensThe Herald - Jun, 27 2018
OncoCyte Corporation (AMEX:OCX) Has Yielded YoY Sales Growth ofPark City Caller - Jun, 26 2018
Is OncoCyte Corporation (AMEX:OCX) Headed For Earnings Growth?The Ledger Gazette - Jun, 24 2018
OncoCyte (OCX) Stock Price Up 37%The Lincolnian Online - Jun, 19 2018
OncoCyte Corp (NYSEAMERICAN:OCX) Sees Significant Decline in Short InterestGenomeWeb - May, 15 2018
OncoCyte Shrinks Q1 Net Loss; Expects Clinical Validation by Year's EndEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
